In-hospital clinical course, outcome and complications among patients vaccinated against COVID-19
https://doi.org/10.29235/1814-6023-2023-20-1-34-41
Abstract
This retrospective case-series analysis evaluated 403 fully vaccinated with Vero Cell or Sputnik V vaccines patients hospitalized in the 6th City Clinical Hospital of Minsk in the period between January 01 and February 28, 2022 with the main diagnosis of “coronavirus infection (COVID-19)”. The diagnosis was confirmed by PCR or SARS-CoV-2 virus antigen tests, as well as chest computed tomography data.
The study revealed higher prevalence of older patients (over 65 years) infected with the SARS-CoV-2 virus and hospitalized in early 2022, at the height of the wave of the pandemic due to the spread of the Omicron variant. Most patients (91.8 %) had moderate symptoms. More than half of them received oxygen support. A relatively small number of inpatient, only 8 persons (1.9 %), were hospitalized in the intensive care unit (ICU) and four of them needed mechanical ventilation. Comorbid conditions and high incidence of mortality (63.5 %) were common in ICU patients. Hypertension and obesity prevailed in the structure of comorbid pathology of all inpatient persons (74.2 and 24.3 %, respectively). Patients of therapeutic departments had relatively short length of stay in the hospital, as well as low in-hospital mortality (0.5 %) and low incidence of complications (5.3 %).
About the Authors
T. I. Kalenchic
Belarusian State Medical University
Belarus
Belarus
Tamara I. Kalenchic – Ph. D. (Med.), Associate Professor
83, Dzerzhinski Ave., 220116, Minsk
S. L. Kabak
Belarusian State Medical University
Belarus
Belarus
Sergey L. Kabak – D. Sc. (Med.), Professor, Head of the Department
83, Dzerzhinski Ave., 220116, Minsk
O. V. Losevich
6th City Clinical Hospital
Belarus
Belarus
Olga V. Losevich – Head of the Emergency Department
5, Ural’skaya Str., 220037, Minsk
M. A. Glazkina
6th City Clinical Hospital
Belarus
Belarus
Margarita A. Glazkina – Doctor of the Emergency Department
5, Ural’skaya Str., 220037, Minsk
References
1. Zhou R., To K. K., Peng Q., Chan J. M., Huang H., Yang D. [et al.]. Vaccine-breakthrough infection by the SARSCoV-2 omicron variant elicits broadly cross-reactive immune responses. Clinical and Translational Medicine, 2022, vol. 12, no. 1, p. e720. https://doi.org/10.1002/ctm2.720
2. Lazareva M. A., Evseeva G. P., Suprun S. V., Lebed’ko O. A. Some features of the transmission of COVID-19 infection in the child population (review). Byulleten’ fiziologii i patologii dykhaniya [Bulletin physiology and pathology of respiration], 2022, vol. 83, pp. 119–131 (in Russian).
3. Liu C., Lee J., Ta C., Soroush A., Rogers J. R., Kim J. H., Natarajan K., Zucker J., Weng C. A. Retrospective analysis of COVID-19 mRNA vaccine breakthrough infections – risk factors and vaccine effectiveness. medRxiv [Preprint], 2021. https://doi.org/10.1101/2021.10.05.21264583
4. Abu-Raddad L. J., Chemaitelly H., Ayoub H. H., Yassine H. M., Benslimane F. M., Al Khatib H. A. [et al.]. Association of prior SARS-CoV-2 infection with risk of breakthrough Infection following mRNA vaccination in Qatar. JAMA, 2021, vol. 326, no. 19, pp. 1930–1939. https://doi.org/10.1001/jama.2021.19623
5. Haas E. J., Angulo F. J., McLaughlin J. M., Anis E., Singer S. R., Khan F. [et al.]. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet, 2021, vol. 397, no. 10287, pp. 1819–1829. https://doi.org/10.1016/S0140-6736(21)00947-8
6. Brosh-Nissimov T., Orenbuch-Harroch E., Chowers M., Elbaz M., Nesher L., Stein M. [et al.]. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clinical Microbiology and Infection, 2021, vol. 27, no. 11, pp. 1652–1657. https://doi.org/10.1016/j.cmi.2021.06.036
7. Kurylev A. A., Zhuravkov A. A., Kolbin A. S. Analysis of the effectiveness of vaccination against COVID-19 based on real-world data in St. Petersburg. Kachestvennaya klinicheskaya praktika [Good clinical practice], 2021, vol. 4, pp. 80–84 (in Russian).
8. Velasco J. M., Vila II V., Diones P. C., Valderama M. T., Mendez C., Turao-Agoncillo M. M. M. [et al.]. Clinical characterization of COVID-19 breakthrough infections, Philippines. Journal of Clinical Virology, 2022, vol. 150–151, art. 105157. https://doi.org/10.1016/j.jcv.2022.105157
9. Duarte L. F., Gálvez N. M. S., Iturriaga C., Melo-González F., Soto J. A., Schultz B. M. [et al.]. Immune profile and clinical outcome of breakthrough cases after vaccination with an inactivated SARS-CoV-2 vaccine. Fronties Immunology, 2021, vol. 12, art. 742914. https://doi.org/10.3389/fimmu.2021.742914
10. Petrikov S. S., Popova I. E., Muslimov R. Sh., Popugaev K. A., Kislukhina E. V., Kokov L. S. Computer tomography in assessing and monitoring the degree of lung injury due to COVID-19. Rossiiskii elektronnyi zhurnal luchevoi diagnostiki = Russian Electronic Journal of Radiology, 2020, vol. 10, no. 2, pp. 14–26 (in Russian).
11. Maslo C., Friedland R., Toubkin M., Laubscher A., Akaloo T., Kama B. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron wave compared with previous waves. JAMA, 2022, vol. 327, no. 6, pp. 583–584. https://doi.org/10.1001/jama.2021.24868
12. Wang L., Berger N. A., Kaelber D. C., Davis P. B., Volkow N. D., Xu R. Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron. medRxiv [Preprint], 2022. https://doi. org/10.1101/2021.12.30.21268495
13. Vieillard-Baron A. et APHP Reality research group. Epidemiological characteristics and severity of omicron variant cases in the aphp critical care units. medRxiv [Preprint], 2022. https://doi.org/10.1101/2022.01.25.22269839
14. Abdullah F., Myers J., Basu D., Tintinger G., Ueckermann V., Mathebula M. [et al.]. Decreased severity of disease during the first global omicron variant COVID-19 outbreak in a large hospital in tshwane, South Africa. International Journal of Infectious Diseases, 2022, vol. 116, pp. 38–42. https://doi.org/10.1016/j.ijid.2021.12.357
15. Bouzid D., Visseaux B., Kassasseya C., Daoud A., Fémy F., Hermand C. [et al.]. Comparison of patients infected with Delta versus Omicron COVID-19 variants presenting to Paris emergency departments: a retrospective cohort study. Annals of Internal Medicine, 2022, vol. 175, no. 6, pp. 831–837. https://doi.org/10.7326/M22-0308
16. Kim M. K., Lee B., Choi Y. Y., Um J., Lee K. S., Sung H. K. [et al.]. Clinical characteristics of 40 patients infected with the SARS-CoV-2 omicron variant in Korea. Journal of Korean Medical Science, 2022, vol. 37, no. 3, p. e31. https://doi. org/10.3346/jkms.2022.37.e31
17. Boitsov S. A., Pogosova N. V., Paleev F. N., Ezhov M. V., Komarov A. L., Pevzner D. V. [et al.]. Clinical characteristics and factors associated with poor outcomes in hospitalized patients with novel coronavirus infection COVID-19. Kardiologiya [Cardiology], 2021, vol. 61, no. 2, pp. 4–14 (in Russian).
18. Modes M. E., Directo M. P., Melgar M., Johnson L. R., Yang H., Chaudhary P. [et al.]. Clinical Characteristics and outcomes among adults hospitalized with laboratory-confirmed SARS-CoV-2 infection during periods of B. 1.617. 2 (Delta) and B. 1.1. 529 (Omicron) variant predominance – One Hospital, California, July 15–September 23, 2021, and December 21, 2021–January 27, 2022. Morbidity and Mortality Weekly Report, 2022, vol. 71, no. 6, pp. 217–223. https://doi.org/10.15585/ mmwr.mm7106e2
19. Malik J. A., Ahmed S., Shinde M., Al-Marmash M. H. S., Alghamdi S., Hussain A., Anwar S. The impact of COVID-19 on the comorbidities: a review of recent updates for combating it. Saudi Journal of Biological Sciences, 2022, vol. 29, no. 5, pp. 3586–3599. https://doi.org/10.1016/j.sjbs.2022.02.006
20. Bajgain K. T., Badal S., Bajgain B. B., Santana M. J. Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature. American Journal of Infection Control, 2021, vol. 49, no. 2, pp. 238–246. https://doi.org/ 10.1016/j.ajic.2020.06.213
21. Kahn F., Bonander C., Moghaddassi M., Rasmussen M., Malmqvist U., Inghammar M., Björk J. Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities – surveillance results from southern Sweden, July 2021 to January 2022. Euro Surveillance, 2022, vol. 27, no. 9, art. 2200121. https://doi. org/10.2807/1560-7917.ES.2022.27.9.2200121
22. Kobelev E., Bergen T. A., Tarkova A. R., Vasil’tseva O. Ya., Kamenskaya O. V., Usov V. Yu., Chernyavskii A. M. COVID-19 as a cause of chronic pulmonary hypertension: pathophysiological rationale and potential of instrumental investigations. Kardiovaskulyarnaya terapiya i profilaktika [Cardiovascular therapy and prevention], 2021, vol. 20, no. 5, pp. 126–133 (in Russian).
23. Mit’kovskaya N. P., Karpov I. A., Arutyunov G. P., Grigorenko E. A., Ruzanov D. Yu., Statkevich T. V., Tarlovskaya E. I. COVID-19 coronavirus infection (overview of international research data). Neotlozhnaya kardiologiya i kardiovaskulyarnye riski [Emergency cardiology and cardiovascular risks], 2020, vol. 4, no. 1, pp. 784–815 (in Russian).
24. Law N., Chan J., Kelly C., Auffermann W. F., Dunn D. P. Incidence of pulmonary embolism in COVID-19 infection in the ED: ancestral, Delta, Omicron variants and vaccines. Emergency Radiology, 2022, vol. 29, no. 4, pp. 625–629. https://doi. org/10.1007/s10140-022-02039-z
Review
For citations:
Kalenchic T.I., Kabak S.L., Losevich O.V., Glazkina M.A. In-hospital clinical course, outcome and complications among patients vaccinated against COVID-19. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2023;20(1):34-41. (In Russ.) https://doi.org/10.29235/1814-6023-2023-20-1-34-41
Views: 281
Email this article 